MK-677 vs ipamorelin: mechanism, evidence, and safety

Last updated 2026-07-24

What are MK-677 and ipamorelin, mechanistically?

Both compounds push the same lever: the growth hormone secretagogue receptor (GHS-R1a), the same receptor ghrelin itself activates. But they are built differently and behave differently in the body. MK-677 (ibutamoren) is a small, non-peptide molecule from the same medicinal chemistry lineage as early orally active GH secretagogues described in the late 1990s ^[1]. It's taken by mouth, absorbed through the gut, and has a long enough half-life that once-daily dosing was the design goal from the start. Ipamorelin is a pentapeptide, not a small molecule. It was characterized in a 1998 European Journal of Endocrinology paper as 'the first selective growth hormone secretagogue,' meaning it stimulates GH release from the pituitary without meaningfully triggering the release of ACTH, cortisol, or prolactin that older secretagogues like GHRP-6 tend to cause ^[2]. That selectivity is the whole reason ipamorelin has the reputation it does. It's also why it's almost always given as an injectable peptide rather than a pill; peptides don't survive oral digestion well, which is a structural reason MK-677 exists as a chemically distinct, orally stable molecule in the first place. Neither drug is human growth hormone. Both work upstream, nudging your own pituitary to release more of its own GH pulses.

MK-677 vs ipamorelin: head-to-head comparison

Which one raises GH and IGF-1 more, and for how long?

This is where the two diverge in shape, more than in size. Ipamorelin produces a sharp, pulsatile GH spike. A pharmacokinetic-pharmacodynamic modeling study in human volunteers described this as a dose-dependent, transient GH release that closely tracked plasma peptide levels, consistent with how the body naturally pulses GH overnight ^[3]. MK-677's whole design premise is the opposite: sustained receptor occupancy over 24 hours because of its long half-life, which is why oral secretagogue chemistry programs in the 1990s specifically optimized for gut absorption and duration rather than a short pulse ^[1]. Neither of these facts comes with a head-to-head human trial comparing IGF-1 outcomes between the two compounds directly; that trial doesn't appear to exist in the peer-reviewed literature at the time of writing. What you have instead is two different pharmacological strategies inferred from separate PK studies, not a shared study arm. Be suspicious of any chart online claiming to show 'MK-677 vs ipamorelin IGF-1 curves' side by side unless it cites an actual comparative trial, because as far as the published record goes, there isn't one.

Is MK-677 or ipamorelin better studied in humans?

Ipamorelin has more depth of mechanistic study, but almost none of it is about bodybuilding-style outcomes. The strongest human data point is a randomized, controlled proof-of-concept study in bowel resection patients, where ipamorelin was tested for managing postoperative ileus, a GI-motility problem, not muscle gain or fat loss ^[4]. That's a real RCT with a real clinical endpoint, but the endpoint is bowel recovery, not body composition. Beyond that, ipamorelin's evidence base is largely rodent and in vitro: longitudinal bone growth in rats ^[5], bone mineral content increases in adult female rats ^[6], reversal of glucocorticoid-induced bone loss in adult rats ^[7], nitrogen balance and urea synthesis effects in steroid-treated rats ^[9], and pancreatic insulin-release mechanisms in normal and diabetic rats ^[8]. A 2020 review in Translational Andrology and Urology discussed GH secretagogues, including ipamorelin, in the context of body composition management in hypogonadal men, but as a discussion of mechanism and rationale rather than a large trial readout ^[10]. MK-677-specific peer-reviewed human trial data is thinner still in this pack's sourcing; most of what circulates online traces back to older orally active secretagogue chemistry papers ^[1] rather than dedicated ibutamoren outcome trials. A 2026 Sports Medicine review on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is explicit that this whole category needs to be read carefully for what's actually approved versus what's marketed ^[11]. If you're deciding based on 'which one has better bro-science reviews,' you're not deciding based on evidence at all.

What do MK-677 and ipamorelin actually do for body composition?

Both are marketed on the promise of more lean mass and less fat, riding on the coattails of what GH itself does. But the direct evidence for either compound producing that outcome in healthy adults is thin, and some of what does exist complicates the simple story. A 2001 study found GH-independent stimulation of adiposity by GH secretagogues, meaning some of the fat-related signaling from this drug class doesn't run purely through the GH-IGF-1 axis the way marketing assumes ^[12]. That's a mechanistic nuance, not proof either drug makes you fatter, but it's a reminder the pharmacology is more tangled than 'more GH equals more muscle, less fat.' The 2020 andrology review frames GH secretagogues as a tool discussed for body composition management specifically in hypogonadal men under medical evaluation, not as a general-population fat-loss shortcut ^[10]. If your actual goal is fat loss or muscle gain and you're comparing these two peptides as if they're interchangeable protein powders, you're missing the point: both act on hormone signaling, not on calories in and out directly.

Which one has more side effect risk: appetite, glucose, water retention?

MK-677's ghrelin-receptor mechanism is the same one that drives hunger, so appetite increase is one of the most consistently reported effects across the secretagogue class broadly, and it tracks with what you'd expect from a ghrelin mimetic acting for a full 24-hour cycle rather than a brief pulse. Blood sugar is the other flag. Ipamorelin's own mechanistic literature includes a study specifically on insulin release from the pancreas in normal and diabetic rats ^[8], which tells you this receptor pathway touches glucose handling, more than GH. A long-acting oral agonist sitting on that receptor all day is a reasonable reason to expect more sustained glucose and insulin effects than a short pulsatile peptide, though a formal comparative human safety trial between the two doesn't exist in the current literature. Water retention, joint puffiness, and mild carpal-tunnel-like symptoms are commonly reported anecdotally with both compounds because they mirror what happens with GH itself, but these are class-level folklore observations from forums and small case reports, not numbers from a controlled trial specifically isolating MK-677 or ipamorelin. For a fuller rundown of documented and reported reactions, see ipamorelin side effects.

Is either MK-677 or ipamorelin FDA-approved?

No, neither is FDA-approved for any indication. You can check this yourself in the Drugs@FDA database, which lists every FDA-approved drug product and does not contain ibutamoren or ipamorelin as approved products [Drugs@FDA database]. What does exist, legally, is a narrower path: certain peptides can be compounded by licensed pharmacies under section 503A of the Food, Drug and Cosmetic Act if the bulk substance appears on FDA's approved bulks list, or is nominated and under evaluation for that list [FDA 503A bulk substances][FDA nominated bulk substances list]. The regulation itself, 21 CFR 216.23, defines the 503A bulks list mechanism, and 21 CFR 216.24 does the same for 503B outsourcing facilities [21 CFR 216.23][21 CFR 216.24]. The compounding authority itself comes from 21 U.S.C. 353a [21 U.S.C. 353a]. This is also the regulatory reason ipamorelin isn't sold as its own standalone product from legitimate pharmacy channels; it's compounded as part of a tesamorelin/ipamorelin blend under a provider's prescription, not marketed with disease-treatment claims the way an approved drug is (a distinction 21 CFR 201.128 spells out in terms of what counts as an 'intended use' claim) [21 CFR 201.128].

What does the black-market and quality-control picture look like?

This is one of the least discussed but most important practical differences between the two. A 2018 analysis of new growth-promoting black market products found meaningful quality and identity problems in unregulated GH secretagogue products circulating outside legitimate pharmacy channels ^[13]. That study wasn't testing ipamorelin or MK-677 specifically branded product lines exclusively, but it's a direct warning about the category both compounds live in when sourced outside a licensed pharmacy: mislabeling, wrong concentration, and contamination risk are documented, not hypothetical. A 2026 JBJS Reviews paper on injectable peptides in sports medicine explicitly frames antidoping and sourcing implications as a structured concern for clinicians dealing with athletes using this drug class ^[14]. And a companion 2026 American Journal of Sports Medicine primer for orthopaedic and sports medicine physicians treats injectable peptide sourcing and quality control as a first-order clinical safety issue, not an afterthought ^[15]. Practically: MK-677 sold as a research-chemical capsule and ipamorelin sold outside a compounding pharmacy both carry this same identity/purity risk. The safer lane for ipamorelin specifically is a provider-reviewed prescription filled by a compounding pharmacy that follows 503A rules, which is a meaningfully different supply chain than a bag of powder from an unregulated seller. See buy ipamorelin for how that pathway actually works.

How is ipamorelin actually dosed and dispensed compared to MK-677?

MK-677 is typically discussed in the unregulated/research literature as an oral daily dose, often in the 10-25 mg range in the bodybuilding and research-chemical marketplace; that dosing convention comes from forum and vendor practice, not a controlled clinical dosing study, so treat it as folklore, not evidence. Ipamorelin, by contrast, has actual human PK-PD modeling behind its dosing logic. The 1999 Pharmaceutical Research study modeled dose-dependent GH release patterns in human volunteers, giving a real pharmacokinetic basis for timing injections around a GH pulse rather than guessing ^[3]. In current compounded practice, ipamorelin is not dispensed alone; it comes as part of a tesamorelin/ipamorelin blend prescribed and reviewed by a provider, then compounded and dosed by weight/volume specific to that blend. If you're trying to work out actual injection volumes, concentrations, and timing for a tesamorelin/ipamorelin blend, don't eyeball it from a forum thread. Use a real reference: ipamorelin dosage and the cjc-1295 ipamorelin dosage calculator walk through the math, and reconstitute cjc ipamorelin covers the actual reconstitution steps, which is where most dosing errors happen in practice, not in the injection itself.

Does MK-677 or ipamorelin help with sleep, recovery, or anti-aging goals?

This is the area with the most marketing and the least direct proof for either compound specifically. GH secretagogues as a drug class are discussed in a 2026 Frontiers in Aging review of therapeutic peptides in gerontology as mechanistically plausible tools for aspects of healthy aging, largely through the GH/IGF-1 axis's known roles in body composition and tissue repair ^[16]. That's a mechanistic and conceptual discussion, not a trial showing either MK-677 or ipamorelin extends healthspan or measurably improves sleep architecture in humans. A separate angle worth knowing: ghrelin receptor agonists including ipamorelin have shown pain-modulating effects in preclinical models, with a 2020 Journal of Experimental Pharmacology study reporting attenuation of visceral and somatic nociception by ghrelin mimetics ^[17]. That's an interesting mechanistic thread connecting this receptor to pain signaling generally, and it's part of why researchers are interested in ipamorelin-class compounds for orthopaedic and postoperative applications, as reflected in a 2026 JAAOS Global Research & Reviews paper on therapeutic peptides in orthopaedics [Ipamorelin Co Editorial Team's read of PMID 41490200]. But 'may modulate pain signaling in animal models' is a long way from 'improves your sleep' or 'slows aging,' and readers should hold that gap firmly in mind.

Which one is right for someone actually deciding between the two?

If your honest goal is oral convenience and you're comfortable with a long-acting ghrelin-receptor agonist sitting on that receptor most of the day, MK-677 is the pharmacologically simpler choice logistically: no reconstitution, no injections, once-daily dosing. If your priority is a cleaner receptor profile with less cortisol/prolactin spillover, and you're working with a provider who can prescribe a compounded blend, ipamorelin (as part of a tesamorelin/ipamorelin formulation) is the better-characterized option in terms of selectivity, based on the original 1998 European Journal of Endocrinology characterization ^[2] and follow-up structure-activity work narrowing down what makes it selective versus older secretagogues like GHRP-6 ^{[18] [1] [19]}. What I would not do is source either one from an unregulated research-chemical seller and self-dose based on forum protocols. The 2018 black-market analysis is a real, documented reason that route carries identity and purity risk you can't verify at home ^[13]. And Ipamorelin Co, for what it's worth, doesn't sell a standalone ipamorelin product for exactly this regulatory reason: it's dispensed only as part of a tesamorelin/ipamorelin blend through a provider-reviewed pathway, filled by a compounding pharmacy partner, not shipped as a bare peptide vial from an anonymous vendor.

What does the newest clinical research say about this whole peptide category?

2026 has been a genuinely active year for review literature trying to bring order to this space. The American Journal of Sports Medicine published an injectable peptide therapy primer aimed specifically at orthopaedic and sports medicine physicians, treating this as a category clinicians need working knowledge of, not a fringe topic ^[15]. Sports Medicine (Auckland) published a safety and efficacy review covering both approved and unapproved peptide therapies for musculoskeletal injury and athletic performance, explicitly separating what's approved from what's marketed ^[11]. JBJS Reviews published a structured narrative review specifically flagging antidoping implications for injectable peptides in competitive sport ^[14]. And the International Journal of Molecular Sciences published a broad review of therapeutic peptides across aesthetic, metabolic, and endocrine conditions in 2026 ^[20]. The throughline across all four: this drug class is real pharmacology worth taking seriously, but the clinical trial base lags a long way behind the marketing enthusiasm, and 'unapproved' is doing a lot of work in most of these paper titles. That's the honest state of the science for both MK-677 and ipamorelin heading into how this space is being discussed by orthopaedic and sports medicine researchers right now.

Frequently asked questions

Is MK-677 stronger than ipamorelin?

Not necessarily 'stronger,' just different in shape. MK-677 gives sustained, all-day ghrelin receptor activation because of its long half-life, while ipamorelin gives a sharp, brief GH pulse shown in human PK-PD modeling ^[13]. No head-to-head human trial directly compares their magnitude, so any claim one is quantitatively 'stronger' isn't backed by a shared study.

Can you take MK-677 and ipamorelin together?

Some protocols stack them, reasoning that oral 24-hour receptor coverage plus a peptide pulse might complement each other, but this combination hasn't been tested in a controlled human trial in the cited literature. It's forum practice, not evidence-based dosing. Anyone considering it should do so under a provider's supervision, not from an online stacking guide.

Is ipamorelin sold as a standalone product?

No. Through legitimate compounding pharmacy channels, ipamorelin is dispensed only as part of a tesamorelin/ipamorelin blend prescribed by a provider, not as a standalone SKU. Anyone selling isolated ipamorelin outside that pathway is operating outside the regulatory framework that governs 503A compounded peptides [21 U.S.C. 353a].

Is MK-677 legal to buy?

MK-677 (ibutamoren) is not FDA-approved for any human use, and it does not appear as an approved product in the Drugs@FDA database. It circulates as a 'research chemical,' which means quality control and legal status vary and buyers have no assurance of product identity or purity outside a regulated pharmacy channel.

Does ipamorelin cause more or less water retention than MK-677?

Neither compound has a controlled human trial directly comparing water retention between them. Both act on GH-related pathways that can cause mild fluid retention as a class effect; reports of this are largely anecdotal for both drugs rather than measured in the peer-reviewed studies cited for either compound.

What is ipamorelin actually FDA-approved to treat?

Nothing. Ipamorelin is not FDA-approved for any indication. The strongest controlled human data on it is a proof-of-concept RCT for postoperative ileus management after bowel resection, which is a research finding, not an approval ^[16].

Why is ipamorelin described as 'selective' in the research?

The original 1998 European Journal of Endocrinology paper coined this description because ipamorelin stimulates pituitary GH release without significantly triggering ACTH, cortisol, or prolactin release, unlike older secretagogues such as GHRP-6 ^[1]. Later structure-activity work traced this selectivity to specific peptide modifications ^[23][22].

Does MK-677 raise blood sugar more than ipamorelin?

There's no direct comparative human trial on this. Ghrelin-receptor activation touches insulin signaling broadly; a rodent study on ipamorelin specifically documented insulin release effects from the pancreas ^[27]. MK-677's 24-hour receptor occupancy is a plausible reason to expect more sustained glucose effects, but this is inference, not a measured comparison.

Is MK-677 the same thing as HGH?

No. MK-677 is a ghrelin receptor agonist that prompts your own pituitary to release GH; it is not growth hormone itself. This is the same mechanistic category ipamorelin belongs to, distinct from injecting exogenous recombinant HGH directly.

How do you dose a tesamorelin/ipamorelin blend?

Dosing depends on the specific compounded concentration your provider prescribes; there's no universal number because it's not a standalone product. For working through actual reconstitution and volume math, see ipamorelin dosage and the cjc-1295 ipamorelin dosage calculator.

What are the biggest documented risks of black-market peptide products?

A 2018 Growth Hormone & IGF Research analysis of new growth-promoting black market products found real identity and quality problems in unregulated secretagogue products, a documented risk applying to both MK-677 and ipamorelin bought outside licensed pharmacy channels ^[17].

Which one has better human clinical trial support, MK-677 or ipamorelin?

Ipamorelin has more peer-reviewed human data, including a randomized controlled proof-of-concept trial for postoperative ileus ^[16] and human PK-PD modeling ^[13]. Dedicated ibutamoren-specific human trial data is thinner in the peer-reviewed record, with most sourcing tracing back to general oral secretagogue chemistry papers ^[10].

Can athletes get flagged for using MK-677 or ipamorelin?

A 2026 JBJS Reviews paper specifically addresses antidoping implications for injectable peptides like ipamorelin in competitive sport, and drug-testing methods for detecting GH secretagogue metabolites in urine have been published for compounds including ipamorelin ^[29][25]. Athletes under testing should assume both compounds carry real detection and doping-rule risk.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin was first characterized as the first selective growth hormone secretagogue, with minimal cortisol/ACTH/prolactin co-release.
2. American Journal of Sports Medicine, 2026 (PMID 41476424): Injectable peptide therapy primer for orthopaedic and sports medicine physicians treats peptide sourcing and clinical use as a first-order issue.
3. Sports Medicine (Auckland), 2026 (PMID 41966639): Review separates approved from unapproved peptide therapies for musculoskeletal injury and athletic performance.
4. Translational Andrology and Urology, 2020 (PMID 32257855): GH secretagogues are discussed for body composition management specifically in hypogonadal men under medical evaluation.
5. International Journal of Molecular Sciences, 2026 (PMID 42123471): Broad 2026 review of therapeutic peptides across aesthetic, metabolic, and endocrine conditions.
6. Frontiers in Aging, 2026 (PMID 42021992): GH secretagogues discussed mechanistically as tools relevant to healthy aging via the GH/IGF-1 axis.
7. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics, including ipamorelin, attenuate visceral and somatic nociception in preclinical models.
8. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes chemistry program developing orally active GH secretagogues, the lineage MK-677 comes from.
9. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induces longitudinal bone growth in rats.
10. Pharmaceutical Research, 1999 (PMID 10496658): PK-PD modeling in human volunteers shows dose-dependent, transient GH release pattern for ipamorelin.
11. Growth Hormone & IGF Research, 2009 (PMID 19231263): Studied nitrogen balance and urea synthesis effects of GH secretagogue treatment in steroid-treated rats.
12. International Journal of Colorectal Disease, 2014 (PMID 25331030): Randomized controlled proof-of-concept trial of ipamorelin for postoperative ileus after bowel resection.
13. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of new growth-promoting black market products found quality and identity problems in unregulated secretagogue products.
14. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats.
15. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Describes a new series of highly potent GH-releasing peptides derived from ipamorelin, informing structure-activity understanding of its selectivity.
16. Drug Testing and Analysis, 2017 (PMID 26811125): Structure-activity relationship work explains what molecular features drive selectivity in peptidic GH secretagogues like ipamorelin.
17. The Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increase bone mineral content in adult female rats.
18. Drug Testing and Analysis, 2015 (PMID 25869809): Metabolites of ipamorelin and other GH-releasing peptides are detectable in human urine after nasal administration, relevant to doping detection.
19. Neuro Endocrinology Letters, 2004 (PMID 15665799): Mechanism study of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats.
20. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues can stimulate adiposity through a GH-independent mechanism.
21. JBJS Reviews, 2026 (PMID 42160466): Structured narrative review of injectable peptides in sports medicine addresses antidoping implications.
22. 21 CFR 216.23, the final 503A Bulks List: Defines the mechanism by which bulk drug substances qualify for use in 503A pharmacy compounding.
23. 21 CFR 216.24, the 503B Bulks List: Defines the parallel bulks list mechanism for 503B outsourcing facilities.
24. 21 U.S.C. 353a, pharmacy compounding: Establishes the statutory authority under which licensed pharmacies may compound drug products like a tesamorelin/ipamorelin blend.
25. 21 CFR 201.128, meaning of intended uses: Defines what marketing claims count as an 'intended use,' relevant to why compounded peptides can't be marketed with disease-treatment claims like an approved drug.
26. FDA, bulk drug substances used in compounding under section 503A: Explains FDA's process for evaluating bulk substances, including peptides, for use in 503A compounding.
27. FDA, bulk drug substances nominated for use in compounding (current list): Lists substances nominated and under FDA evaluation for the 503A bulks list.
28. Drugs@FDA database: Confirms neither ibutamoren (MK-677) nor ipamorelin appears as an FDA-approved drug product.